UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2019
Commission File Number: 0-24260
Amedisys, Inc.
(Exact name of registrant as specified in charter)
Delaware | 11-3131700 | |
(State or other jurisdiction | (IRS Employer | |
of incorporation or organization) | Identification No.) |
3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, par value $0.001 per share | AMED | The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECTION 5 CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
Amedisys, Inc. (the Company) held its annual meeting of stockholders on Friday, June 7, 2019 (the Annual Meeting). At the Annual Meeting, the Companys stockholders voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.
Proposal 1. The Companys stockholders elected the following seven directors for a term of one year. There were 1,709,902 broker non-votes with respect to the proposal.
Nominee |
For | Withheld | ||||||
Julie D. Klapstein |
27,402,198 | 493,543 | ||||||
Paul B. Kusserow |
27,723,903 | 171,838 | ||||||
Richard A. Lechleiter |
27,280,166 | 615,575 | ||||||
Jake L. Netterville |
27,085,716 | 810,025 | ||||||
Bruce D. Perkins |
27,422,642 | 473,099 | ||||||
Jeffrey A. Rideout, MD |
27,422,092 | 473,649 | ||||||
Donald A. Washburn |
27,122,627 | 773,114 |
Proposal 2. The Companys stockholders ratified the selection of KPMG LLP as the Companys independent registered public accountants for the fiscal year ending December 31, 2019. There were no broker non-votes with respect to the proposal.
For |
Against |
Abstain | ||
29,370,632 | 224,480 | 10,531 |
Proposal 3. The Companys stockholders approved, on an advisory (non-binding) basis, the compensation paid to the Companys named executive officers. There were 1,709,902 broker non-votes with respect to the proposal.
For |
Against |
Abstain | ||
27,118,941 | 750,435 | 26,365 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMEDISYS, INC. | ||
By: | /s/ Paul B. Kusserow | |
Paul B. Kusserow | ||
President and Chief Executive Officer | ||
DATE: June 13, 2019 |